Andy Cohen TRT: Photographic Before/After Analysis and What the Science Says

Who Is Andy Cohen and What Has He Said About TRT?

Andy Cohen is the creator and longtime executive vice president of Bravo programming, the host of "Watch What Happens Live," and a bestselling author. He is not a private figure on health topics. Cohen discussed his TRT use openly on his SiriusXM radio show "Radio Andy," describing fatigue and low libido in his mid-to-late 40s as the symptoms that led him to seek evaluation. He credited TRT with restoring his energy and improving his body composition.

That public disclosure makes him a useful case study. His face and physique have been photographed thousands of times at red-carpet events, on television, and at public appearances, providing a time-stamped photographic record that spans his pre-TRT and post-TRT periods.

What Cohen Actually Said

Cohen has described symptoms consistent with hypogonadism: persistent fatigue, reduced motivation, and a difficulty maintaining the muscle mass he had in his 30s. These are precisely the symptoms the Endocrine Society clinical practice guideline on male hypogonadism lists as indications for TRT evaluation in symptomatic men with confirmed low serum testosterone [1].

He has not publicly disclosed his exact testosterone levels, delivery method, or prescribing clinician. The analysis below therefore focuses on observable photographic changes and maps those against what the peer-reviewed literature says those changes represent clinically.

The Photographic Record: What Changes Are Visible?

Public photographs from 2019 through 2024 show a consistent directional shift in Andy Cohen's physique. The changes are not dramatic in the way dramatic surgical alterations are. They are the subtler changes that TRT-associated body recomposition tends to produce over 12 to 36 months.

Lean Mass and Mid-Section Composition

Photographs from approximately 2019 to 2021 show Cohen with a softer mid-section typical of age-related reductions in testosterone and the associated shift toward central adiposity. By 2023 and 2024, shirtless and form-fitting-shirt photographs show a visibly more defined torso with less abdominal fullness.

This pattern is consistent with published data. A meta-analysis of 58 randomized controlled trials (N=3,867) published in the Journal of Clinical Endocrinology and Metabolism found that TRT in hypogonadal men produced a mean reduction in fat mass of 1.6 kg and a mean increase in lean mass of 1.6 kg over 6 to 12 months [2]. The effect on visceral fat is particularly relevant: a 52-week RCT (N=170) published in the European Journal of Endocrinology showed a statistically significant reduction in visceral adipose tissue measured by CT scan in men receiving testosterone undecanoate injections compared to placebo [3].

Facial Appearance and Skin Quality

Cohen's skin quality in photographs from 2023 and 2024 appears firmer and less lax around the jawline compared to photographs from 2018 and 2019. Testosterone receptors are present in human skin fibroblasts, and androgen signaling upregulates collagen synthesis. A review published in Dermatology and Therapy noted that androgen deficiency is associated with reduced dermal collagen density and that TRT may partially reverse this in men with documented hypogonadism [4].

Aging, sun protection habits, and skincare routines also affect skin quality. Attributing all visible improvement to TRT alone would be inaccurate. Cohen has also discussed weight training, dietary changes, and other wellness practices publicly.

Energy and Functional Appearance

This is harder to quantify photographically, but video appearances on "Watch What Happens Live" from 2022 onward show Cohen visibly more animated and physically present compared to interviews from 2019 where he discussed burnout and fatigue. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials at 12 U.S. Sites (N=790, mean age 72), found that testosterone treatment improved sexual function scores and self-reported energy significantly compared to placebo over 12 months [5]. Cohen is younger than the TTrials population, which means the magnitude of benefit could differ in either direction.

What a Standard TRT Protocol Looks Like for a Man in Cohen's Profile

Cohen has not disclosed specific protocol details. Based on his age (mid-50s at the time he began discussing TRT) and the symptoms he described, a clinician following the Endocrine Society guidelines would likely consider the following approach [1].

Diagnosis First

The Endocrine Society recommends confirming hypogonadism with two morning fasting serum total testosterone measurements below 300 ng/dL on separate days, along with a clinical symptom burden consistent with deficiency [1]. Measurement must occur before 10:00 a.m. Due to the diurnal variation in testosterone secretion. A single low result is insufficient for diagnosis.

Common Delivery Methods

Three delivery routes dominate clinical practice for men in Cohen's demographic:

• Intramuscular injection: Testosterone cypionate 100 to 200 mg every 7 to 14 days, or testosterone enanthate at similar dosing. Cost-effective and produces predictable serum peaks. The FDA approved testosterone cypionate for hypogonadism under NDA 005551 [6].
• Transdermal gel (e.g., AndroGel 1.62%): 20.25 to 81 mg applied daily to shoulders or upper arms. Produces steadier serum levels without injection-related peaks. FDA-approved labeling specifies target trough levels of 400 to 700 ng/dL [7].
• Subcutaneous pellet implants (e.g., Testopel): 150 to 450 mg implanted every 3 to 6 months. Less frequent dosing. FDA approved under NDA 008823 [8].

Target Serum Levels

The Endocrine Society guideline recommends titrating to a mid-normal range total testosterone of approximately 400 to 700 ng/dL [1]. Levels above 700 ng/dL without clinical justification increase the risk of erythrocytosis and cardiovascular strain without additional symptomatic benefit.

Monitoring Protocol

Men on TRT require monitoring every 3 to 6 months for the first year, then annually. The standard panel includes serum total testosterone, hematocrit (target below 54%), PSA, and a lipid panel. The TRAVERSE trial (N=5,246, mean age 57), published in the New England Journal of Medicine in 2023, found no statistically significant increase in major adverse cardiovascular events in men with hypogonadism randomized to testosterone gel versus placebo over a mean follow-up of 33 months, though men with recent cardiovascular events were excluded [9]. Hematocrit elevation (greater than 54%) was more common in the testosterone group (6.5% vs. 4.4%, P<0.001), reinforcing the need for routine monitoring.

What TRT Can and Cannot Do: Managing Realistic Expectations

The photographic changes visible in Cohen's public record fit within the expected range of outcomes from properly managed TRT in a symptomatic hypogonadal man. They do not indicate supraphysiologic use. The changes do not include the rapid and extreme muscle hypertrophy associated with anabolic steroid abuse.

What TRT Realistically Produces

A 2021 systematic review in the Cochrane Database (36 trials, N=2,399) found that TRT in men with hypogonadism produced modest but consistent improvements in lean body mass, sexual function, mood, and bone mineral density compared to placebo [10]. The operative word is modest. TRT is not a dramatic body transformation tool. It returns a deficient hormonal environment to a normal physiologic range.

For a man in his early-to-mid 50s who is simultaneously doing resistance training and eating a protein-adequate diet, the combination produces visible but proportionate changes over 12 to 24 months. That matches what the photographic record shows for Cohen.

What TRT Does Not Do

TRT does not independently produce the level of muscularity seen in bodybuilding or competitive physique athletes. It does not directly reduce subcutaneous fat in the absence of caloric deficit. It does not eliminate the need for resistance training to stimulate lean mass accrual.

A landmark RCT by Bhasin et al. Published in NEJM (N=61, graded testosterone doses over 20 weeks) established the dose-response relationship between testosterone and muscle mass. Fat-free mass increased linearly with testosterone dose, but even at supraphysiologic doses (600 mg/week), the gains without exercise were modest (3.2 kg) compared to physiologic doses plus resistance training [11]. That trial remains the foundational evidence for understanding TRT's contribution to body composition.

The Role of Lifestyle

Cohen has been photographed at SoulCycle and has discussed a generally active lifestyle. The lean mass changes visible in his photographs likely reflect the synergistic effect of physiologic testosterone restoration combined with consistent resistance and cardiovascular exercise, not TRT alone.

Is Cohen's Visible Change Within Normal Clinical Parameters?

Yes. The changes observable in the photographic record, a modest reduction in abdominal fullness, improved muscle definition, better skin tone, and visibly higher energy in video appearances, are all within the expected clinical range of physiologic TRT in a symptomatic man.

Signs That Would Suggest Supraphysiologic Use

For clinical context, observable signs that suggest doses above the physiologic replacement range include:

• Rapid, disproportionate muscle hypertrophy over 6 to 12 months
• Visible gynecomastia (from aromatase overload without an aromatase inhibitor)
• Severe acne on the back and shoulders
• Notable frontotemporal hair recession accelerating rapidly
• Polycythemia symptoms such as facial redness and visible vascular prominence

None of these signs are consistently present across Cohen's photographic record. The changes documented are gradual and proportionate.

Signs Consistent with Physiologic TRT

Changes consistent with physiologic testosterone replacement in a previously hypogonadal man include:

• Gradual lean mass accrual of 1 to 3 kg over 12 months
• Reduction in central adiposity without extreme fat loss
• Improved skin firmness and tone
• More consistent energy and mood in public-facing media
• No dramatic alteration in facial structure or voice

The photographic record over 2019 to 2024 is consistent with this profile.

Risks, Monitoring, and the Ethical Dimension of Celebrity Disclosure

Cohen's openness about TRT is worth examining in its own right. Physician organizations have expressed concern about TRT use in men without confirmed biochemical hypogonadism. The Endocrine Society states explicitly: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations" [1].

The Prescribing Concern

TRT prescriptions in the United States increased by roughly 300% between 2001 and 2013, driven partly by direct-to-consumer advertising and by men self-reporting symptoms without confirmed biochemical testing [12]. The FDA issued a safety communication in 2015 requiring all prescription testosterone products to carry labeling clarifying that they are approved only for men with low testosterone caused by certain medical conditions, not for age-related decline alone [13].

Cohen's disclosure does not specify whether his diagnosis met formal criteria. Clinically responsible coverage of his case must note that difference.

What Men Considering TRT Should Do

Any man considering TRT based on celebrity disclosure should undergo two fasting morning serum testosterone measurements, a full history and physical, and evaluation of secondary causes of low testosterone including hypothyroidism, hyperprolactinemia, and pituitary pathology before initiating therapy. The American Urological Association and the Endocrine Society both publish clinical practice guidelines that outline this workup in detail [1].

Key Clinical Takeaways From the Andy Cohen Case

Andy Cohen's public discussion of TRT and the photographic record that accompanies his years in the public eye provide a real-world illustration of what physiologic testosterone replacement looks like in a man in his 50s who is also exercising regularly. The changes are real, gradual, and consistent with the published literature.

They are not evidence of anything beyond that. A 2016 NEJM paper reporting the TTrials results noted that testosterone treatment improved bone density, sexual function, and walking capacity but did not show a significant cardiovascular benefit in older men [5]. The risk-benefit calculation is individualized, not universal.

Men who see Cohen's transformation and consider TRT should ask their clinician to order two morning fasting total testosterone levels before any prescription is written. If both results fall below 300 ng/dL in the context of consistent symptoms, the Endocrine Society guidelines support a trial of therapy with the monitoring schedule described above [1].